Se connecter Inscription gratuite

Inhibrx RPE

Quel est le RPE de Inhibrx?

Le RPE de Inhibrx, Inc. est $17.481k

Quelle est la définition de RPE?

Le revenu par employé (RPE) est le revenu divisé par le nombre d'employés d'une organisation.

RPE des entreprises dans Health Care secteur sur NASDAQ par rapport à Inhibrx

Que fait Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Entreprises avec rpe similaire à Inhibrx